IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs
This study has been completed.
Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborator:
Swiss Cohort
Information provided by:
The HIV Netherlands Australia Thailand Research Collaboration
ClinicalTrials.gov Identifier:
NCT00477308
First received: May 20, 2007
Last updated: June 4, 2010
Last verified: June 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In HIV-NAT 013 phase I study, genotyping was performed in 95 children on dual NRTI which showed that almost all children had resistance to NRTi. The HIV-NAT 013 phase II is a follow up study to evaluate treatment outcome after salvage therapy and the evolution of mutations.
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Procedure: salvage therapy | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic |
| Official Title: | Clinical, Immunologic and Virological Outcomes of Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs |
Resource links provided by NLM:
Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:
Primary Outcome Measures:
- Clinical, immunologic and virologic outcome of children who had genotyping directed salvage therapy [ Time Frame: 1 time point (Cross Sectional Study) ]
Secondary Outcome Measures:
- Comparison outcome of children in the 3 groups, [ Time Frame: 1 time point ]
- Changes of mutation in children within the 3 groups, and [ Time Frame: 1 time point ]
- Effect of previously unreported mutations, minor and others, on treatment outcome [ Time Frame: 1 time point ]
| Enrollment: | 95 |
| Study Start Date: | January 2006 |
| Study Completion Date: | April 2009 |
| Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
The HIV-NAT 013 study (conducted in 2003) evaluated prevalence and pattern of RT mutation in 95 children treated with dual NRTI. The study showed almost all children to have some degree of NRTI resistance and 40% with multi NRTI resistance. The mutation reported was major mutation.
After the study, the patients were managed based on the physician's judgment using genotyping results. The 95 patients in HIV-NAT 013 are categorized into 3 groups.
- No viral resistance
- Low grade resistance with or without clinical/ immunological failure
- High grade resistance with or without clinical/ immunological failure.
There are limited prospective studies evaluating outcome of decision regarding salvage therapy after genotyping results
There are also new mutations that are not considered major mutation that may affect treatment outcome
Knowledge learned from this study will benefit Thai children with NRTI resistance by helping pediatricians better choose salvage treatment options
Eligibility| Ages Eligible for Study: | 1 Year to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- All children from HIV-NAT 013 phase I
Exclusion Criteria:
- No inform consent obtained
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00477308
Please refer to this study by its ClinicalTrials.gov identifier: NCT00477308
Locations
| Thailand | |
| Chulalongkorn Hospital | |
| Bangkok, Thailand, 10330 | |
| Queen Sirikit National Institute of Child Health, Bangkok | |
| Bangkok, Thailand, 10330 | |
| The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) | |
| Bangkok, Thailand, 10330 | |
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Swiss Cohort
Investigators
| Principal Investigator: | Kiat Ruxrungtham, MD | The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) |
| Principal Investigator: | Tawee Chotpitayasunondh, MD | Queen Sirikit National Institute of Child Health, Bangkok |
More Information
Additional Information:
Publications:
| Responsible Party: | Kiat Ruxrungtham, HIV-NAT |
| ClinicalTrials.gov Identifier: | NCT00477308 History of Changes |
| Other Study ID Numbers: |
HIV-NAT 013 phase II |
| Study First Received: | May 20, 2007 |
| Last Updated: | June 4, 2010 |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
|
HIV children genotypic resistance dual NRTIs Salvage therapy |
treatment outcome Salvage therapy based on genotyping results Treatment Failure |
Additional relevant MeSH terms:
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
ClinicalTrials.gov processed this record on August 17, 2017